NVN Liquidation Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Scott Plesha

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Scott Plesha (58 yo)

less than a year

Mandato

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
John Gay	Chief Financial Officer	5.3yrs	US$568.23k	0.17% $ 0.05
Scott Plesha	CEO & Director	less than a year	Nessun dato	Nessun dato
Carri Geer	Senior VP & CTO	5.3yrs	Nessun dato	Nessun dato
Sai Rangarao	Senior VP	less than a year	Nessun dato	Nessun dato
Tomoko Maeda-Chubachi	Chief Medical Officer	2.8yrs	Nessun dato	Nessun dato
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	Nessun dato	Nessun dato

1.6yrs

Durata media

Gestione esperta: Il team dirigenziale di 0A4P non è considerato esperto (durata media 1.6 anni), il che suggerisce un nuovo team.

NVN Liquidation Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.71 loss in 1Q 2022)

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.74 loss in FY 2021)

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.39 loss in 2Q 2021)

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

First quarter 2022 earnings released: US$0.71 loss per share (vs US$0.60 loss in 1Q 2021)

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.63 loss in 3Q 2020)

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media